Prediction of the Stage Shift Growth of Early-stage Lung Adenocarcinomas by Volume-doubling Time

Overview

Journal Quant Imaging Med Surg

Specialty Radiology

Date 2024 Jun 7

PMID 38846271

Authors

En-Kuei Tang

Yun-Ju Wu

Chi-Shen Chen

Fu-Zong Wu

Affiliations

Soon will be listed here.

Abstract

Background: Prediction of subsolid nodule (SSN) interval growth is crucial for clinical management and decision making in lung cancer screening program. To the best of our knowledge, no study has investigated whether volume doubling time (VDT) is an independent factor for predicting SSN interval growth, or whether its predictive power is better than that of traditional semantic methods, such as nodular diameter or type. This study aimed to investigate whether VDT could provide added value in predicting the long-term natural course of SSNs (<3 cm) regarding stage shift.

Methods: This retrospective study enrolled 132 patients with spectrum lesions of lung adenocarcinoma who underwent two consecutive computed tomography (CT) examinations before surgical tissue proofing between 2012 and 2021 in Kaohsiung Veterans General Hospital. The VDTs were manually calculated from the volumetric segmentation using Schwartz's approximation formula. We utilized logistic regression to identify predictors associated with stage shift progression based on the VDT parameter.

Results: The average duration of follow-up period was 3.629 years. A VDT-based nomogram model (model 2) based on CT semantic features, clinical characteristics, and the VDT parameter yielded an area under the curve (AUC) of 0.877 [95% confidence interval (CI): 0.807-0.928]. Compared with model 1 (CT semantic features and clinical characteristics), model 2 exhibited the better predictive performance for stage shift (AUC model 1: 0.833 versus AUC model 2: 0.877, P=0.047). In model 2, significant predictors of stage shift growth included initial nodule size [odds ratio (OR) =4.074, 95% CI: 1.368-12.135; P=0.012], SSN classification (OR =0.042; 95% CI: 0.006-0.288; P=0.001), follow-up period (OR =1.692, 95% CI: 1.337-2.140; P<0.001), and VDT classification (OR =2.327, 95% CI: 1.368-3.958; P=0.002). For the stage shift, the mean progression time for the VDT (>400 d) group was 7.595 years, and median progression time was 7.430 years. Additionally, a VDT ≤400 d is an important prognostic factor associated with aggressive growth behavior with a stage shift.

Conclusions: VDT is crucial for predicting SSN stage shift growth irrespective of clinical and CT semantic features. This highlights its significance in informing follow-up protocols and surgical planning, emphasizing its prognostic value in predicting SSN growth.

Citing Articles

Multi-type classification of lung nodules based on CT radiomics and ensemble learning for diversity weighting.

Tang G, Du L, Ling S, Che Y, Chen X Quant Imaging Med Surg. 2024; 14(12):8942-8965.

PMID: 39698682 PMC: 11651971. DOI: 10.21037/qims-24-1315.

References

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Wu F, Wu Y, Chen C, Tang E . Prediction of Interval Growth of Lung Adenocarcinomas Manifesting as Persistent Subsolid Nodules ≤3 cm Based on Radiomic Features. Acad Radiol. 2023; 30(12):2856-2869. DOI: 10.1016/j.acra.2023.02.033. View

Hong J, Park S, Kim H, Goo J, Park I, Kang C . Volume and Mass Doubling Time of Lung Adenocarcinoma according to WHO Histologic Classification. Korean J Radiol. 2020; 22(3):464-475. PMC: 7909861. DOI: 10.3348/kjr.2020.0592. View

Lim W, Ridge C, Nicholson A, Mirsadraee S . The 8 lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant Imaging Med Surg. 2018; 8(7):709-718. PMC: 6127520. DOI: 10.21037/qims.2018.08.02. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Park S, Lee S, Kim S, Lee J, Choi S, Do K . Volume Doubling Times of Lung Adenocarcinomas: Correlation with Predominant Histologic Subtypes and Prognosis. Radiology. 2020; 295(3):703-712. DOI: 10.1148/radiol.2020191835. View

Ricciardi S, Booton R, Petersen R, Infante M, Scarci M, Veronesi G . Managing of screening-detected sub-solid nodules-a European perspective. Transl Lung Cancer Res. 2021; 10(5):2368-2377. PMC: 8182699. DOI: 10.21037/tlcr.2020.03.37. View

Qi L, Wu B, Tang W, Zhou L, Huang Y, Zhao S . Long-term follow-up of persistent pulmonary pure ground-glass nodules with deep learning-assisted nodule segmentation. Eur Radiol. 2019; 30(2):744-755. DOI: 10.1007/s00330-019-06344-z. View

Heuvelmans M, Vliegenthart R, de Koning H, Groen H, van Putten M, Yousaf-Khan U . Quantification of growth patterns of screen-detected lung cancers: The NELSON study. Lung Cancer. 2017; 108:48-54. DOI: 10.1016/j.lungcan.2017.02.021. View

10.

Kim H, Jung K, Lim K, Lee S, Jun J, Kim J . Lung Cancer Screening with Low-Dose CT in Female Never Smokers: Retrospective Cohort Study with Long-term National Data Follow-up. Cancer Res Treat. 2017; 50(3):748-756. PMC: 6056956. DOI: 10.4143/crt.2017.312. View

11.

Wu Y, Wu F, Yang S, Tang E, Liang C . Radiomics in Early Lung Cancer Diagnosis: From Diagnosis to Clinical Decision Support and Education. Diagnostics (Basel). 2022; 12(5). PMC: 9139351. DOI: 10.3390/diagnostics12051064. View

12.

Lowenstein L, Godoy M, Erasmus J, Zirari Z, Bennett A, Leal V . Implementing Decision Coaching for Lung Cancer Screening in the Low-Dose Computed Tomography Setting. JCO Oncol Pract. 2020; 16(8):e703-e725. PMC: 7427416. DOI: 10.1200/JOP.19.00453. View

13.

Rota M, Pizzato M, La Vecchia C, Boffetta P . Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis. Ann Oncol. 2019; 30(7):1040-1043. DOI: 10.1093/annonc/mdz145. View

14.

Rahal Z, El Nemr S, Sinjab A, Chami H, Tfayli A, Kadara H . Smoking and Lung Cancer: A Geo-Regional Perspective. Front Oncol. 2017; 7:194. PMC: 5585135. DOI: 10.3389/fonc.2017.00194. View

15.

Wu F, Huang Y, Wu Y, Tang E, Wu M, Chen C . Prognostic effect of implementation of the mass low-dose computed tomography lung cancer screening program: a hospital-based cohort study. Eur J Cancer Prev. 2020; 29(5):445-451. DOI: 10.1097/CEJ.0000000000000569. View

16.

Tan M, Ma W, Sun Y, Gao P, Huang X, Lu J . Prediction of the Growth Rate of Early-Stage Lung Adenocarcinoma by Radiomics. Front Oncol. 2021; 11:658138. PMC: 8082461. DOI: 10.3389/fonc.2021.658138. View

17.

Kobayashi Y, Sakao Y, Deshpande G, Fukui T, Mizuno T, Kuroda H . The association between baseline clinical-radiological characteristics and growth of pulmonary nodules with ground-glass opacity. Lung Cancer. 2013; 83(1):61-6. DOI: 10.1016/j.lungcan.2013.10.017. View

18.

Detterbeck F . The eighth edition TNM stage classification for lung cancer: What does it mean on main street?. J Thorac Cardiovasc Surg. 2017; 155(1):356-359. DOI: 10.1016/j.jtcvs.2017.08.138. View

19.

Nawa T, Nakagawa T, Mizoue T, Kusano S, Chonan T, Fukai S . Long-term prognosis of patients with lung cancer detected on low-dose chest computed tomography screening. Lung Cancer. 2011; 75(2):197-202. DOI: 10.1016/j.lungcan.2011.07.002. View

20.

Tang E, Chen C, Wu C, Wu M, Yang T, Liang H . Natural History of Persistent Pulmonary Subsolid Nodules: Long-Term Observation of Different Interval Growth. Heart Lung Circ. 2018; 28(11):1747-1754. DOI: 10.1016/j.hlc.2018.08.015. View